the staff of the Ridgewood blog
Jacksonville FL, the Food and Drug Administration granted approval on Friday to a two-year plan that permits Florida to import certain prescription drugs from Canada at a lower cost compared to the U.S. This landmark approval is viewed as a move towards reducing medication costs for American consumers and opens the door for other states to seek authorization for importing prescription drugs from Canada.
This development coincides with the ongoing federal examination of the U.S. drug-pricing system, which contributes to the highest per capita out-of-pocket spending on prescription drugs globally. Previous findings by the U.S. Government Accountability Office revealed that prices for selected brand-name drugs in the U.S. were, on average, two to four times higher than the prices for the same drugs in Australia, Canada, and France.
While Florida anticipates saving an estimated $150 million in the first year of its bulk importation program, it is important to note that the FDA must approve the specific drugs sought by Florida before the importation shipments can commence. It’s worth mentioning that the pharmaceutical industry’s principal lobbying group expressed opposition to the FDA’s decision on Friday.
The FDA’s approval for Florida signifies a recognition that foreign suppliers can securely provide medications to Americans, setting the stage for other states to seek similar approvals. Apart from Florida, eight states with existing laws enabling drug importation await FDA approval, with some, like Colorado, having already submitted applications. States seeking approval must demonstrate that importing medications would effectively lower consumer prices and that the drugs meet FDA safety standards.
However, the path forward is uncertain, as pharmaceutical lobbyists are expected to legally challenge the FDA’s decision for Florida. Additionally, some manufacturers currently prohibit Canadian companies from selling their products across the border.
While importing drugs may not be a panacea, experts argue that the root cause of high drug costs in the U.S. lies in patent protections that grant pharmaceutical companies extended monopolies on drug production. The Inflation Reduction Act, allowing the government to negotiate prices with pharmaceutical manufacturers, is seen as a more effective means of cost reduction compared to imports, according to University of Michigan Law School expert Nicholas Bagley, who referred to Florida’s plan as “political theater.”
Critics also point out that Canada’s pharmaceutical market is insufficient to meet the needs of all Americans. Canada has already taken steps to limit exports of scarce drugs. Additionally, concerns are raised that lower drug prices might diminish manufacturers’ incentive to produce them, potentially leading to shortages, as noted by industry experts.
the Ridgewood blog has a brand-new twitter account, we tweet good sh$t
https://twitter.com/tRidgewoodblog
#news #follow #media #breakingnews #trending #viral #newsupdate #info #currentaffairs #newspaper
